Table 2 Hazard ratios, confidence intervals, and p values for death or incident MI prediction for traditionally defined poor MH and novel plasma biomarkers in the overall cohort and stratified by BMI category.
From: Novel plasma biomarkers improve discrimination of metabolic health independent of weight
Model* | Overall cohort | Lean | Overweight | Obese | ||||
|---|---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
Unadjusted model | ||||||||
MH | 1.38 (1.28–1.49) | 4.5 × 10−17 | 1.23 (1.08–1.39) | 1.4 × 10−3 | 1.45 (1.28–1.64) | 7.2 × 10−9 | 1.53 (1.32–1.77) | 2.0 × 10−8 |
MH + LDL-P | 0.91 (0.88–0.94) | 2.5 × 10−8 | 0.91 (0.85–0.97) | 5.3 × 10−3 | 0.88 (0.83–0.94) | 3.3 × 10−5 | 0.93 (0.88–0.98) | 8.1 × 10−3 |
MH + LP-IR | 0.78 (0.75–0.81) | 3.1 × 10−40 | 0.75 (0.70–0.82) | 3.3 × 10−12 | 0.79 (0.74–0.84) | 2.5 × 10−14 | 0.79 (0.75–0.83) | 1.3 × 10−17 |
MH + GlycA | 1.27 (1.24–1.31) | 2.9 × 10−59 | 1.28 (1.21–1.35) | 6.2 × 10−19 | 1.32 (1.26–1.39) | 2.8 × 10−27 | 1.23 (1.17–1.29) | 2.4 × 10−16 |
MH + HMSP | 0.66 (0.64–0.68) | 3.6 × 10−123 | 0.67 (0.63–0.72) | 9.6 × 10−34 | 0.63 (0.60–0.67) | 1.4 × 10−49 | 0.67 (0.63–0.71) | 1.1 × 10−44 |
MH + BCAA | 0.91 (0.86–0.96) | 3.3 × 10−4 | 0.94 (0.85–1.04) | 0.23 | 0.93 (0.85–1.02) | 0.13 | 0.87 (0.80–0.94) | 6.3 × 10−4 |
MH + SCDAs | 1.25 (1.20–1.30) | 5.1 × 10−29 | 1.15 (1.06–1.24) | 6.9 × 10−4 | 1.3 (1.23–1.38) | 3.7 × 10−19 | 1.31 (1.22–1.41) | 2.5 × 10−13 |
Fully adjusted model** | ||||||||
MH + clinical covariates** | 1.21 (1.11–1.31) | 5.3 × 10−6 | 1.04 (0.9–1.19) | 0.61 | 1.22 (1.07–1.40) | 3.6 × 10−3 | 1.53 (1.3–1.81) | 4.4 × 10−7 |
MH + LDL-P + clinical covariates** | 0.8 (0.73–0.87) | 7.2 × 10−7 | 0.72 (0.6–0.87) | 4.6 × 10−4 | 0.71 (0.61–0.83) | 1.5 × 10−5 | 0.97 (0.84–1.12) | 0.66 |
MH + LP-IR + clinical covariates** | 0.83 (0.80–0.87) | 1.1 × 10−18 | 0.8 (0.73–0.87) | 8.7 × 10−7 | 0.84 (0.78–0.90) | 4.6 × 10−7 | 0.84 (0.78–0.89) | 3.2 × 10−8 |
MH + GlycA + clinical covariates** | 1.27 (1.23–1.31) | 1.6 × 10−49 | 1.25 (1.18–1.33) | 9.1 × 10−14 | 1.3 (1.24–1.38) | 1.1 × 10−21 | 1.24 (1.18–1.31) | 2.0 × 10−16 |
MH + HMSP + clinical covariates** | 0.71 (0.68–0.74) | 1.4 × 10−70 | 0.68 (0.63–0.73) | 2.7 × 10−24 | 0.71 (0.66–0.76) | 2.2 × 10−25 | 0.72 (0.68–0.77) | 4.0 × 10−25 |
MH + BCAA + clinical covariates** | 0.94 (0.89–1.00) | 0.051 | 0.92 (0.81–1.03) | 0.14 | 0.97 (0.88–1.08) | 0.62 | 0.95 (0.87–1.04) | 0.29 |
MH + SCDAs + clinical covariates** | 1.24 (1.14–1.34) | 9.2 × 10−7 | 1.23 (1.06–1.41) | 4.7 × 10−3 | 1.36 (1.19–1.55) | 6.2 × 10−6 | 1.05 (0.87–1.28) | 0.61 |
